Biopharmaceutical company Transcenta Holding Limited (Transcenta) (HKEX:06628), a provider of antibody-based therapeutics, reported on Wednesday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to its high affinity humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody, Osemitamab (TST001), to treat pancreatic cancer patients.
Transcenta stated that this is the second Orphan Drug Designation for Osemitamab (TST001) and followins its 2021 designation for the treatment of gastric cancer and gastroesophageal junction cancer.
The company added that pancreatic cancer is often diagnosed at an advanced stage with typically poor outcomes to available therapies. The 5-year survival rate at diagnosis is around 10% and the median overall survival barely exceeds 9 months for advanced or metastatic disease.
Earlier, Transcenta presented preliminary anti-tumor activity data in pancreatic cancer of Osemitamab (TST001), which indicated that monotherapy treatment with Osemitamab (TST001) led to a prolonged partial response in a Claudin18.2 low expressing pancreatic cancer patient who progressed from multiple cycles of chemotherapy. In preclinical studies, Osemitamab (TST001) has shown potent anti-tumor activities in Claudin18.2 expressing pancreatic cancer tumor models independent of Kras mutation status.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval